Profusa Receives ISO 13485:2016 Certificate from GMEDGlobeNewsWire · Oct 15, 2026
Head to Head Review: OraSure Technologies (NASDAQ:OSUR) and Profusa (NASDAQ:PFSA)Defense World · Sep 25, 2026
Micro Cap Profusa Navigates European Regulatory Hurdles to Advance Oxygen Monitoring TechBenzinga · Sep 24, 2026
Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early OctoberGlobeNewsWire · Sep 24, 2026
Profusa, Inc. Receives Nasdaq Compliance DeterminationGlobeNewsWire · Sep 15, 2026
Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares RequirementGlobeNewsWire · Aug 31, 2026Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid.